Clinical Trial

Universal CAR-T Cells (BRL-301) in Relapse or Refractory Autoimmune Diseases

Enrolling by Invitation
View on ClinicalTrials.gov →
Summary
This is an investigator initiated trial to assess the efficacy and safety of BRL-301 in the relapse or refractory autoimmune diseases of China.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2023-05-07; most recent amendment 2024-11-18.
Status change: Recruiting → Enrolling by Invitation 2024-11-18
Trial Details
NCT Number NCT05859997
Lead Sponsor Bioray Laboratories
Collaborators: Shanghai Changzheng Hospital
Conditions Systemic Lupus Erythematosus (SLE), Sjogren's Syndrome, Systemic Sclerosis, Inflammatory Myopathy, ANCA Associated Systemic Vasculitis, Antiphospholipid Syndrome
Enrollment 15 participants
Start Date 2023-05-17
Primary Completion 2024-05-27 (estimated)
Study Completion 2025-05-27 (estimated)
Updated on ClinicalTrials.gov 2024-11-20